Systemic Immuno-Inflammation Index May Predict the Burden of Coronary Artery Disease

Abstract

Background: Atherosclerosis has a significant place in the pathophysiology of coronary artery disease. In clinical practice, complete blood count is considered as a routine laboratory technique that can be easily applied. Systemic immune inflammatory index (SII), which can be easily calculated with this laboratory method, can be used to evaluate the balance of inflammation, considering the multifaceted effects of atherosclerosis. Aim: In our investigation, we purposed to determine the relationship between the intensity of inflammation, which we calculated with whole blood using this biomarker in 166 patients, and the intensity of coronary artery disease, which was evaluated with coronary angiography. Method: 166 patients who underwent coronary angiography because of acute coronary syndrome were included in our investigation. SYNTAX scores of the patients were calculated using the application on the website (http://www.SYNTAXcore.com.) SYNTAX scores are divided into 3 groups: 0-22, low; 23-32, medium; 33 and above, high. In our study, we divided the SYNTAX score into two groups: 0-22 was defined as low, 23 and above as medium-high. We examined the relationship between the SII and the low and medium-high groups. Findings: In patients consulting with acute coronary syndrome, a statistically significant positive result was found between the coronary artery disease assessed with Systemic immune inflammatory index (SII) and SYNTAX (Synergy Between PCI With TAXUS and Cardiac Surgery) score. (p=0.022) Conclusion: SII calculation is a practical method and can provide the clinicians with important clues about the prevalence of acute coronary syndrome in terms of treatment management; however, more in-depth, well-designed studies are required for SII.

Keywords

• Acute Coronary Syndrome
• Systemic immune inflammatory index (SII)
• SYNTAX (Synergy Between PCI With TAXUS and Cardiac Surgery) score

References

1. 1.World Health Organisation. Global HealthEstimates: Life Expectancy and Leading Causes ofDeath and Disability. Available online:https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates (accessed on 26July 2022).
2. 2.Piironen M, Ukkola O, Huikuri H, et al. Trends inLong-term Prognosis After Acute CoronarySyndrome. Eur J Prev Cardiol. 2017;24(3):274-80.doi: 10.1177/2047487316679522.
3. 3.Lei H, Xu S, Mao X, et al. Systemicimmuneinflammatory index as a predictor of lymphnode metastasis in endometrial cancer. J InflammRes. (2021) 14:7131–42. doi: 10.2147/jir.S345790
4. 4.Karaçalılar M, Demir M. A novel predictor inpatients undergoing heart valve surgery: systemicinflammation response index: a single center cross-sectional study. Eur Rev Med Pharmacol Sci. (2023)27(3):1016–22. doi: 10.26355/eurrev_202302_31196
5. 5.Peng Y, Huang W, Shi Z, Chen Y, Ma J. Positiveassociation between systemic immune-inflammatory index and mortality of cardiogenicshock. Clin Chim Acta. (2020) 511:97–103. doi:10.1016/j.cca.2020.09.022
6. 6.You Y, Chen Y, Fang W, et al. The associationbetween sedentary behavior, exercise, and sleepdisturbance: a mediation analysis of inflammatorybiomarkers. Front Immunol. (2022) 13:1080782.doi: 10.3389/fimmu. 2022.1080782
7. 7.Crea F, Liuzzo G. Anti-inflammatory Treatment ofAcute Coronary Syndromes: The Need for PrecisionMedicine. Eur Heart J. 2016;37(30):2414-6. doi:10.1093/eurheartj/ehw207.
8. 8.Budzianowski J, Pieszko K, Burchardt P,Rzeźniczak J, Hiczkiewicz J. The Role ofHematological Indices in Patients with AcuteCoronary Syndrome. Dis Markers.2017;2017:3041565. doi: 10.1155/2017/3041565.

9. 9.Hu B, Yang XR, Xu Y, et al. Systemicimmuneinflammation index predicts prognosis ofpatients after curative resection for hepatocellularcarcinoma. Clin Cancer Res. (2014) 20(23):6212–22.doi: 10.1158/ 1078-0432.Ccr-14-0442
10. 10.Demir M, Özbek M. A novel predictor in patientswith coronary chronic total occlusion: systemicimmune-inflammation index: a single-center cross-sectional study. Rev Assoc Med Bras (1992). 2022May;68(5):579-585. doi: 10.1590/1806-9282.20211097.
11. 11.Roffi M, Patrono C, Collet JP, et al. 2015 ESCGuidelines for the Management of Acute CoronarySyndromes in Patients Presenting WithoutPersistent ST-segment Elevation: Task Force for theManagement of Acute Coronary Syndromes inPatients Presenting without Persistent ST-SegmentElevation of the European Society of Cardiology(ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ ehv320.
12. 12.Yumuk V, Tsigos C, Fried M, et al. EuropeanGuidelines for Obesity Management in Adults. Obes.Facts 2015, 8, 402–24.
13. 13.Stergiou G.S, Palatini P, Parati G, et al. 2021European Society of Hypertension practiceguidelines for office and out-of-office blood pressure measurement. J. Hypertens. 2021, 39, 1293–302.
14. 14.Cosentino F, Grant P.J, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, andcardiovascular diseases developed in collaborationwith the EASD. Eur. Heart J. 2020, 41, 255–323.
15. 15.Mach F, Baigent C, Catapano A.L, et al. 2019ESC/EAS Guidelines for the management ofdyslipidaemias: Lipid modification to reducecardiovascular risk. Eur. Heart J. 2020, 41, 111–88.
16. 16.Collet J.-P, Thiele H, Barbato E, et al. 2020 ESCGuidelines for the management of acute coronarysyndromes in patients presenting withoutpersistent ST-segment elevation. Eur. Heart J. 2021,42, 1289–367.
17. 17.Lawton J.S, Tamis-Holland J.E, Bangalore S, et al.2021 ACC/AHA/SCAI Guideline for Coronary ArteryRevascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2022, 79, e21–e129.
18. 18.Choi DH, Kobayashi Y, Nishi T, et al. Combinationof Mean Platelet Volume and Neutrophil toLymphocyte Ratio Predicts Long-Term MajorAdverse Cardiovascular Events After PercutaneousCoronary Intervention. Angiology. 2019;70(4):345-51.doi: 10.1177/0003319718768658.
19. 19.Crea F, Libby P. Acute Coronary Syndromes: TheWay Forward from Mechanisms to PrecisionTreatment. Circulation 2017, 136, 1155–66.
20. 20.Ridker P.M, Everett B.M, Thuren T, et al.Antiinflammatory Therapy with Canakinumab forAtherosclerotic Disease. N. Engl. J. Med. 2017, 377,1119–31.
21. 21.Kim J.H, Lim S, Park K.S, et al. Total anddifferential WBC counts are related with coronaryartery atherosclerosis and increase the risk forcardiovascular disease in Koreans. PLoS ONE 2017,12, e0180332.
22. 22.Shah A.D, Denaxas S, Nicholas O, Hingorani A.D,Hemingway H. Neutrophil Counts and InitialPresentation of 12 Cardiovascular Diseases: ACALIBER Cohort Study. J. Am. Coll. Cardiol. 2017, 69,1160–9.
23. 23.Fernández-Ruiz I. Neutrophil-driven SMC deathdestabilizes atherosclerotic plaques. Nat. Rev.Cardiol. 2019, 16, 455.
24. 24.Wu M.Y, Li C.J, Hou M.F, Chu P.Y. New Insightsinto the Role of Inflammation in the Pathogenesis ofAtherosclerosis. Int. J. Mol. Sci. 2017, 18, 2034.
25. 25.Nardin M, Verdoia M, Laera N, Cao D, De Luca G.New Insights into Pathophysiology and New RiskFactors for ACS. J Clin Med. 2023 Apr 14;12(8):2883. doi: 10.3390/jcm12082883. PMID: 37109221;PMCID: PMC10146393.
26. 26.Yang YL, Wu CH, Hsu PF, et al. Systemic Immune-inflammation Index (SII) Predicted Clinical Outcomein Patients with Coronary Artery Disease. Eur J ClinInvest. 2020;50(5):e13230. doi: 10.1111/eci.13230.